What is the Epstein-Barr virus?
The Epstein-Barr virus (EBV), also known as human herpesvirus 4, belongs to the herpesvirus family. Its genetic material consists of double-stranded DNA, which is surrounded by a sort of capsule made up of a protein structure, known as the capsid, which in turn has a shell covered with surface proteins that protrude outwards like spikes. These spikes help the viruses to attach themselves to cells and penetrate them. When this happens, the virus can trigger various illnesses. This has long been known in the case of Pfeiffer’s glandular fever, which mainly affects adolescents and young adults (the ‘kissing disease’). Furthermore, EBV also plays a role in the development of lymphoma (such as Burkitt’s lymphoma or non-Hodgkin’s lymphoma) and can contribute to the development of malignant tumours in the nasopharynx. It has also recently been established that the Epstein-Barr virus is most likely not only a risk factor but actually a trigger for multiple sclerosis (MS). Over the course of their lives, more than 90 per cent of all people become infected with EBV. This usually occurs during childhood, often has no consequences and therefore frequently goes unnoticed in such cases. However, as herpes viruses generally remain in the body once infection has occurred, this also applies to the Epstein-Barr virus. Even if it does not trigger an active infection, the immune system cannot completely eliminate it, but can keep it in check.
How is it transmitted?
The Epstein-Barr virus is primarily transmitted via saliva, particularly through kissing. However, objects that have come into contact with infected saliva are also a possible source of infection. These can include, for example, cutlery, cups, glasses, toothbrushes or even children’s toys. However, the virus only survives on these surfaces if there is sufficient moisture. This means that dry objects no longer pose a risk of infection. Other sources of infection include blood transfusions and sexual contact. The virus is infectious even before the first symptoms appear and can remain so for weeks after the symptoms have subsided. As the body cannot completely eliminate EBV, it is difficult to determine exactly when a person is no longer infectious; however, the immune system can usually keep the virus in check after a few weeks to the extent that saliva is no longer infectious.
Is there a vaccine?
There is currently no vaccine against the Epstein-Barr virus, but research into potential vaccine candidates has been ongoing for some time.
Diagnosis of EBV infection
As far as diagnosing EBV is concerned, the diagnosis is usually made on the basis of symptoms. A blood test can detect an increase in white blood cells (leucocytosis) as well as specific types of T-cells (Pfeiffer cells). There are also tests for antibodies in the blood; however, these are normally only carried out when the diagnosis is unclear and they also make it possible to distinguish between a recent and a past EBV infection.
How can an acute infection be recognised?
The infection usually occurs during childhood and is generally asymptomatic. Only around ten to 20 per cent of people go on to develop symptoms later in life, and even then, in many cases there are no long-term consequences. However, particularly in adolescents and young adults, a recent infection may present as Pfeiffer’s glandular fever (mononucleosis). The condition causes cold-like symptoms, is often mistaken for a cold and therefore frequently goes undetected. Typical symptoms of Pfeiffer’s glandular fever include:
- Fever
- Fatigue
- Sore throat
- Swollen lymph nodes
- swollen spleen
- possibly joint pain and a rash
However, some patients experience serious complications such as shortness of breath, a ruptured spleen or anaemia. The condition can also take a very protracted course, which may be accompanied, for example, by chronic fatigue syndrome. Another condition that can be triggered by the Epstein-Barr virus is oral hairy leukoplakia, although this only occurs in immunocompromised individuals, particularly those with HIV. Symptoms of this condition include white patches on the tongue that cannot be scraped off. Furthermore, EBV is associated with a specific form of lymph node cancer, known as Burkitt’s lymphoma. This is characterised by rapid tumour growth and involvement of the cervical lymph nodes, leading to severe swelling of the lymph nodes. EBV can be regarded as a risk factor for the development of such a cancer, but it is not the sole cause. Furthermore, the Epstein-Barr virus may contribute to the development of nasopharyngeal carcinoma. This refers to malignant tumours of the nasopharyngeal mucosa, although other factors such as smoking or alcohol consumption, as well as a genetic predisposition, also play a role. It has also been shown that multiple sclerosis (MS) could be triggered by infection with the Epstein-Barr virus. Until recently, it was thought that the virus was one of several risk factors. Recently, however, studies have shown that the extent to which EBV influences the development of multiple sclerosis is many times greater than previously thought. MS symptoms are extremely varied and range from visual disturbances and paralysis to pain, amongst other things.
Treatment of an Epstein-Barr virus infection
As EBV remains in the body after a single infection, there is no direct treatment in the form of a medicine that kills the virus. An EBV infection is therefore incurable, but the consequences of the associated conditions can be treated symptomatically. For example, painkillers are used for infectious mononucleosis, whilst cancer treatments are used for nasopharyngeal carcinoma. Nasopharyngeal carcinoma can often be treated surgically, and the symptoms of MS are managed using, amongst other things, cortisone, beta-interferons or monoclonal antibodies.